Discovery of a potent and long-acting Xenopus GLP-1-based GLP-1/glucagon/Y2 receptor triple agonist

Peptide 3b demonstrated superior effects on lipid metabolism, body weight, and glycemic control in diet-induced obesity mice compared to other agonists.

• Peptide 3b is a unimolecular triple agonist targeting GLP-1, glucagon, and Y receptors.
• This peptide reduced food intake without causing nausea in behavioral tests.
• In diet-induced obesity mice, a lower dose of 3b was more effective than higher doses of various single and dual agonists.
• 3b exhibited balanced activities for both GCGR and GLP-1R, along with selective YR activity.
• The findings indicate potential for peptide 3b as a novel treatment for obesity and type 2 diabetes.

AI simplified